Loading data for VOGX — first visit, this takes a few seconds.
Vogenx Inc. (VOGX)
NasdaqCM: VOGX
· Echtzeitkurs · USD
18.20
+2.45 (15.56%)
Zum Schluss: Aug 18, 2026, 2:49 PM
Vogenx Inc. (VOGX) Stock Price, Analysis & Data
15.56% (1D)
Keine Daten verfügbar
| Geld | n/a |
| Marktkapitalisierung | 253.08 Mio |
| Umsatz (TTM) | n/a |
| Nettogewinn (TTM) | -1.56 Mio |
| Beta | n/a |
| EPS (ttm) | -0.2 |
| KGV (TTM) | n/a |
| Forward-KGV | n/a |
| KBV (TTM) | -68.42 |
| KUV (TTM) | n/a |
| Earnings Date | n/a |
| Brief | n/a |
| Volumen | 329,369 |
| Ø Vol. (20D) | 208,550 |
| Eröffnung | 18.63 |
| Vortagesschluss | 15.75 |
| Tagesspanne | 17.51 - 19.04 |
| 52-Wk Range | 12.95 - 19.04 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über VOGX
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorpora...
Branche Biotechnology
Sektor Healthcare
IPO Datum Aug 12, 2026
Mitarbeiter 4
Börse NasdaqCM
Tickersymbol VOGX
Website https://vogenx.com
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von Vogenx 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -1.45 Mio, ein Rückgang von -34.4 %.
Finanzberichte